| | Pfizer Inc. |
| | 235 East 42nd Street |
| | New York, N.Y. 10017-5755 |
August 8, 2011
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Jim B. Rosenberg
| | Re: | Pfizer Inc. |
| | | Form 10-K for Fiscal Year Ended December 31, 2010 |
| | | Filed February 28, 2011 |
| | | |
| | | Form 10-Q for the Quarterly Period Ended April 3, 2011 |
| | | Filed May 12, 2011 |
| | | |
| | | File No. 001-03619 |
Dear Mr. Rosenberg:
This letter is to confirm the receipt of your letter dated August 5, 2011 regarding our July 7, 2011 response to your original comment letter dated April 13, 2011, regarding the filings referenced above. The Company believes that it will be able to provide you with a full response on or before September 2, 2011.
Please do not hesitate to contact me at 212-733-3222 with any questions or comments you may have.
| | Very truly yours, |
| | |
| | /s/ Loretta V. Cangialosi |
| | Loretta V. Cangialosi |
| | Senior Vice President and Controller |
| cc: | Frank A. D’Amelio |
| | Executive Vice President, Business Operations and Chief Financial Officer |
| | |
| | Larry P. Bradley |
| | Partner - KPMG LLP |
